Abstract
Introduction: Psoriatic disease phenotypes range from low–high disease activity, with/without concomitant psoriatic arthritis (PsA)—heterogeneity that influences responses to biologic therapies. Secukinumab, a fully human monoclonal antibody that selectively neutralizes interleukin-17A, has been shown to have significant efficacy in the treatment of moderate to severe plaque psoriasis and PsA.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
